Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

GLUEMonte Rosa Therapeutics, Inc.

Nasdaq · CIK 0001826457
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts277

Identity from submissions API

NameMonte Rosa Therapeutics, Inc.
CIK0001826457
TickersGLUE
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN000000000
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone617-949-2643
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • Monte Rosa Therapeutics, Inc. (2020-09-29T04:00:00.000Z → 2026-11-16T05:00:00.000Z)
Business address
321 HARRISON AVENUE
SUITE 900
BOSTON
MA
02118
MA
Mailing address
321 HARRISON AVENUE
SUITE 900
BOSTON
MA
02118
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

405 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-464030 005-92649 261563381 34 17931
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000902664-26-004583 005-92649 261561441 34 10883
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-003182 005-92649 261561246 34 23693
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000080255-26-000719 005-92649 261556485 34 7763
2026-11-05 10-Q 10-Q 0001193125-26-448568 001-40522 261524757 34 10956704 1 1
2026-11-05 8-K 8-K 2.02,9.01 0001193125-26-448527 001-40522 261524686 34 498219 1 1
2026-10-06 4 4 0001193125-26-415540 4922
2026-10-01 8-K 8-K 7.01,8.01,9.01 0001193125-26-409833 001-40522 261428946 34 21650261 1 1
2026-09-08 8-K 8-K 7.01,8.01,9.01 0001193125-26-384360 001-40522 261363342 34 246414 1 1
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-005533 005-92649 261282253 34 16396
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000902664-26-003506 005-92649 261281587 34 15113
2026-08-06 10-Q 10-Q 0001193125-26-336711 001-40522 261245941 34 10781591 1 1
2026-08-06 8-K 8-K 2.02,9.01 0001193125-26-336681 001-40522 261245891 34 499801 1 1
2026-07-17 4 4 0001193125-26-307791 5090
2026-07-16 4 4 0001193125-26-306110 9080
2026-07-16 144 xsl144X01/primary_doc.xml 0001950047-26-007144 001-40522 261180402 33 6819
2026-07-15 144 xsl144X01/primary_doc.xml 0001969223-26-000786 001-40522 261177519 33 6985
2026-07-08 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000080255-26-000442 005-92649 261161374 34 7765
2026-07-07 4 4 0001193125-26-297558 10303
2026-07-06 4 4 0001193125-26-296490 9364
2026-07-06 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001072613-26-000558 005-92649 261157188 34 88067
2026-07-01 4 4 0001193125-26-292767 8571
2026-06-30 144 xsl144X01/primary_doc.xml 0001950047-26-006665 001-40522 261141061 33 6933
2026-06-30 4 4 0001193125-26-290486 8387
2026-06-30 4 4 0001193125-26-290484 14161
2026-06-29 144 xsl144X01/primary_doc.xml 0001950047-26-006612 001-40522 261136444 33 6215
2026-06-29 144 xsl144X01/primary_doc.xml 0001950047-26-006574 001-40522 261135658 33 5503
2026-06-25 4 4 0001193125-26-282740 20551
2026-06-25 4 4 0001193125-26-282735 8557
2026-06-25 4 4 0001193125-26-282736 8398
2026-06-24 144 xsl144X01/primary_doc.xml 0001950047-26-006456 001-40522 261116332 33 5730
2026-06-23 144 xsl144X01/primary_doc.xml 0001950047-26-006428 001-40522 261111400 33 5365
2026-06-23 144 xsl144X01/primary_doc.xml 0001969223-26-000720 001-40522 261111033 33 6353
2026-06-23 144 xsl144X01/primary_doc.xml 0001950047-26-006406 001-40522 261111005 33 6976
2026-06-18 4 4 0001193125-26-275806 8557
2026-06-18 4 4 0001193125-26-275805 8375
2026-06-17 144 xsl144X01/primary_doc.xml 0001969223-26-000711 001-40522 261098254 33 5722
2026-06-12 4 4 0001193125-26-269885 5385
2026-06-12 4 4 0001193125-26-269365 5530
2026-06-12 4 4 0001193125-26-269354 5472
2026-06-12 4 4 0001193125-26-269378 5474
2026-06-12 4 4 0001193125-26-269349 5485
2026-06-12 4 4 0001193125-26-269348 5455
2026-06-12 4 4 0001193125-26-269368 5478
2026-06-11 8-K 8-K 5.07 0001193125-26-267465 001-40522 261082941 34 188290 1 1
2026-06-02 4 4 0001193125-26-253472 7172
2026-06-02 144/A xsl144X01/primary_doc.xml 0001965301-26-000067 001-40522 261053868 33 5764
2026-06-01 144 xsl144X01/primary_doc.xml 0001965301-26-000066 001-40522 261051327 33 6289
2026-06-01 4 4 0001193125-26-251395 8874
2026-05-29 144 xsl144X01/primary_doc.xml 0001950047-26-005288 001-40522 261044819 33 5022
2026-05-28 4 4 0001193125-26-245728 8557
2026-05-27 144 xsl144X01/primary_doc.xml 0001969223-26-000596 001-40522 261026017 33 5091
2026-05-26 4 4 0001193125-26-239240 8557
2026-05-22 4 4 0001193125-26-236840 8076
2026-05-22 144 xsl144X01/primary_doc.xml 0001969223-26-000590 001-40522 261013477 33 4460
2026-05-21 144 xsl144X01/primary_doc.xml 0001950047-26-004881 001-40522 261008257 33 4752
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-226862 005-92649 26988163 34 17764
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-062588 005-92649 26987922 34 16036
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-001394 005-92649 26987406 34 25182
2026-05-07 10-Q 10-Q 0001193125-26-210358 001-40522 26950890 34 9174434 1 1
2026-05-07 8-K 8-K 2.02,9.01 0001193125-26-210298 001-40522 26950803 34 453240 1 1
2026-05-05 4 4 0001193125-26-206344 5267
2026-05-01 144 xsl144X01/primary_doc.xml 0001965301-26-000046 001-40522 26933526 33 5680
2026-04-29 ARS ARS 0001193125-26-191481 001-40522 26915770 34 20570501
2026-04-29 DEFA14A DEFA14A 0001193125-26-191451 001-40522 26915677 34 4963350 1 1
2026-04-29 DEF 14A DEF 14A 0001193125-26-191439 001-40522 26915599 34 12776457 1 1
2026-04-22 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-170903 005-92649 26884880 34 36349
2026-04-16 144 xsl144X01/primary_doc.xml 0001950047-26-003550 001-40522 26867594 33 8457
2026-04-15 4 4 0001193125-26-156981 5073
2026-04-14 144 xsl144X01/primary_doc.xml 0001950047-26-003455 001-40522 26861300 33 5553
2026-04-13 144 xsl144X01/primary_doc.xml 0001950047-26-003392 001-40522 26857876 33 9461
2026-04-10 4 4 0001193125-26-151254 5090
2026-04-09 144 xsl144X01/primary_doc.xml 0001950047-26-003347 001-40522 26851611 33 4737
2026-04-08 144 xsl144X01/primary_doc.xml 0001950047-26-003308 001-40522 26848184 33 6967
2026-04-07 4 4 0001193125-26-145545 7415
2026-04-07 3 3 0001193125-26-145520 26451
2026-03-19 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001072613-26-000294 005-92649 26774214 34 78601
2026-03-17 S-8 S-8 0001193125-26-110712 333-294401 26767021 33 783915 1 1
2026-03-17 10-K 10-K 0001193125-26-109360 001-40522 26759072 34 35843474 1 1
2026-03-17 8-K 8-K 2.02,9.01 0001193125-26-109353 001-40522 26759058 34 516522 1 1
2026-03-05 4 4 0001193125-26-094296 4781
2026-03-04 4 4 0001193125-26-091733 5131
2026-03-04 144 xsl144X01/primary_doc.xml 0001193125-26-091704 001-40522 26722232 33 6493
2026-03-02 4 4 0001193125-26-085677 13214
2026-03-02 144 xsl144X01/primary_doc.xml 0001965301-26-000022 001-40522 26708084 33 5679
2026-03-02 144 xsl144X01/primary_doc.xml 0001950047-26-001966 001-40522 26707809 33 6222
2026-02-27 144 xsl144X01/primary_doc.xml 0001950047-26-001887 001-40522 26700153 33 5483
2026-02-24 4 4 0001193125-26-066955 4420
2026-02-23 144 xsl144X01/primary_doc.xml 0001950047-26-001676 001-40522 26666700 33 7243
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-26-000461 005-92649 26641416 34 23712
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-016412 005-92649 26641227 34 15011
2026-02-11 S-3ASR S-3ASR 0001193125-26-046690 333-293389 26621364 33 1276437 1 1
2026-02-10 8-K 8-K 5.02 0001193125-26-044616 001-40522 26615804 34 168146 1 1
2026-01-21 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001012975-26-000062 005-92649 26545595 34 16061
2026-01-09 8-K 8-K 1.01,8.01,9.01 0001193125-26-009005 001-40522 26523446 34 677062 1 1
2026-01-09 424B5 424B5 0001193125-26-009001 333-285942 26523430 33 655453
2026-01-09 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001193125-26-008951 005-92649 26523282 34 18564
2026-01-09 4 4 0001193125-26-008902 8938
2026-01-08 144/A xsl144X01/primary_doc.xml 0001965301-26-000002 001-40522 26519031 33 5146
2026-01-07 144 xsl144X01/primary_doc.xml 0001965301-26-000001 001-40522 26516389 33 4457
2026-01-07 8-K 8-K 8.01,9.01 0001193125-26-006341 001-40522 26515910 34 169018 1 1
2026-01-07 424B5 424B5 0001193125-26-006297 333-285942 26515778 33 657328
2026-01-07 8-K 8-K 7.01,8.01,9.01 0001193125-26-005420 001-40522 26513948 34 14037425 1 1
2026-01-05 4 4 0001193125-26-002406 9454
2026-01-05 4 4 0001193125-26-002401 9464
2026-01-05 4 4 0001193125-26-002390 5280
2026-01-05 4 4 0001193125-26-002389 9423
2026-01-05 4 4 0001193125-26-002386 9623
2026-01-05 4 4 0001193125-26-002385 9444
2026-01-05 144 xsl144X01/primary_doc.xml 0001193125-26-002369 001-40522 26505752 33 4546
2025-12-16 8-K 8-K 7.01,8.01,9.01 0001193125-25-319981 001-40522 251573356 34 12173587 1 1
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000080255-25-000838 005-92649 251483462 34 7647
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-004946 005-92649 251481692 34 10067
2025-11-12 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001193125-25-277603 005-92649 251472863 34 17212
2025-11-06 10-Q 10-Q 0001193125-25-268045 001-40522 251456093 34 12247925 1 1
2025-11-06 8-K 8-K 2.02,7.01,9.01 0001193125-25-268042 001-40522 251456079 34 500391 1 1
2025-10-31 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000102909-25-000255 005-92649 251438824 34 6300
2025-10-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001193125-25-242555 005-92649 251401160 34 115667
2025-10-03 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001012975-25-000601 005-92649 251372802 34 29309
2025-09-15 8-K 8-K 1.01,7.01,9.01 0001193125-25-202760 001-40522 251313152 34 215507 1 1
2025-08-21 UPLOAD filename1.pdf 0000000000-25-008933 001-40522 39744
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003581 005-92649 251214272 34 10670
2025-08-07 10-Q 10-Q 0000950170-25-104550 001-40522 251191539 34 10451389 1 1
2025-08-07 8-K 8-K 2.02,9.01 0000950170-25-104545 001-40522 251191516 34 472502 1 1
2025-07-22 CORRESP filename1.htm 0000950170-25-097510 247371
2025-07-15 UPLOAD filename1.pdf 0000000000-25-007429 001-40522 43746
2025-06-16 4 4 0000950170-25-086727 35296
2025-06-16 4 4 0000950170-25-086704 5318
2025-06-16 4 4 0000950170-25-086703 5335
2025-06-16 4 4 0000950170-25-086702 5348
2025-06-16 4 4 0000950170-25-086701 5341
2025-06-16 4 4 0000950170-25-086700 5323
2025-06-16 4 4 0000950170-25-086699 5397
2025-06-13 8-K 8-K 5.07 0000950170-25-086129 001-40522 251046364 34 187976 1 1
2025-06-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-001639 005-92649 251029175 34 11501
2025-06-04 4 4 0000950170-25-081637 5278
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-25-001549 005-92649 25954281 34 23700
2025-05-08 10-Q 10-Q 0000950170-25-066372 001-40522 25923835 34 8290589 1 1
2025-05-08 8-K 8-K 2.02,7.01,9.01 0000950170-25-066370 001-40522 25923831 34 37337187 1 1
2025-04-25 ARS ARS 0000950170-25-058691 001-40522 25873736 34 33762907
2025-04-25 DEFA14A DEFA14A 0000950170-25-058689 001-40522 25873705 34 3414928
2025-04-25 DEF 14A DEF 14A 0000950170-25-058686 001-40522 25873629 34 13547644 1 1
2025-04-16 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-25-002493 005-92649 25843690 34 17440
2025-03-31 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000901 333-285942 25796314 33 1780
2025-03-27 CORRESP filename1.htm 0001193125-25-065485 6552
2025-03-26 UPLOAD filename1.pdf 0000000000-25-003255 333-285942 40147
2025-03-25 4 4 0000950170-25-044633 4363
2025-03-20 S-3 S-3 0001193125-25-058423 333-285942 25754721 33 1264877
2025-03-20 S-8 S-8 0000950170-25-042346 333-285940 25754671 33 191338
2025-03-20 10-K 10-K 0000950170-25-042344 001-40522 25754659 34 31765596 1 1
2025-03-20 8-K 8-K 2.02,7.01,9.01 0000950170-25-042319 001-40522 25754464 34 38254651 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-000984 005-92649 25623914 34 10710
2025-02-04 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-000642 005-92649 25587840 34 11825
2025-01-31 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-25-000213 005-92649 25579936 34 38662
2025-01-30 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000196 005-92649 25575672 34 6179
2025-01-10 8-K 8-K 2.02,7.01,9.01 0000950170-25-003776 001-40522 25520353 34 37719733 1 1
2025-01-06 4 4 0000950170-25-002105 7329
2025-01-06 4 4 0000950170-25-002103 7329
2025-01-06 4 4 0000950170-25-002102 7494
2025-01-06 4 4 0000950170-25-002101 7339
2025-01-06 4 4 0000950170-25-002100 7297
2025-01-06 4 4 0000950170-25-002099 7319
2024-12-13 4 4 0000950170-24-136056 5276
2024-12-13 3 3 0000950170-24-136055 14837
2024-12-13 8-K 8-K 5.02 0000950170-24-136042 001-40522 241546777 34 172010 1 1
2024-12-05 8-K 8-K 7.01,8.01,9.01 0000950170-24-133525 001-40522 241527806 34 37588463 1 1
2024-11-14 SC 13G/A glue13gasep24.txt 0000080255-24-001467 005-92649 34 7155
2024-11-12 SC 13G/A filing.txt 0000315066-24-002827 005-92649 241444867 34 8235
2024-11-07 10-Q 10-Q 0000950170-24-122780 001-40522 241433117 34 7969934 1 1
2024-11-07 8-K 8-K 2.02,9.01 0000950170-24-122766 001-40522 241433077 34 468288 1 1
2024-10-30 SC 13D/A SC 13D/A 0001193125-24-247656 005-92649 241411408 34 113360
2024-10-30 4 4 0000950170-24-119051 38188
2024-10-28 144 xsl144X01/primary_doc.xml 0001973141-24-000523 001-40522 241400880 33 4461
2024-10-28 8-K 8-K 1.01,7.01,9.01 0000950170-24-117567 001-40522 241398411 34 225394 1 1
2024-09-24 SC 13D/A SC 13D/A 0001193125-24-224875 005-92649 241320749 34 112359
2024-09-24 4 4 0000950170-24-109112 16024
2024-09-13 4 4 0000950170-24-106532 20002
2024-09-13 4 4 0000950170-24-106387 5597
2024-08-12 SC 13D/A NEW ENTERPRISE ASSOCIATES 17, L.P. -- MONTE ROSA THERAPEUTICS 13D/A(#2) 0001072613-24-000618 005-92649 241198352 34 452279
2024-08-12 SC 13D/A SC 13D/A 0001193125-24-198980 005-92649 241197850 34 112172
2024-08-08 10-Q 10-Q 0000950170-24-093296 001-40522 241185966 34 7753644 1 1
2024-08-08 8-K 8-K 2.02 0000950170-24-093294 001-40522 241185959 34 465278 1 1
2024-07-09 4 4 0000950170-24-082416 5285
2024-06-27 8-K 8-K 7.01,9.01 0000950170-24-078159 001-40522 241075357 34 220784 1 1
2024-06-13 4 4 0000950170-24-073265 32889
2024-06-13 4 4 0000950170-24-073064 5404
2024-06-13 4 4 0000950170-24-073073 5348
2024-06-13 4 4 0000950170-24-073063 5330
2024-06-13 4 4 0000950170-24-073062 5342
2024-06-13 4 4 0000950170-24-073059 5355
2024-06-12 8-K 8-K 5.07 0000950170-24-072407 001-40522 241038337 34 182380 1 1
2024-06-05 4 4 0000950170-24-069310 5287
2024-06-05 4 4 0000950170-24-069309 5370
2024-06-05 4 4 0000950170-24-069308 5378
2024-06-05 4 4 0000950170-24-069307 5398
2024-06-05 3 3 0000950170-24-069283 20329
2024-06-05 3 3 0000950170-24-069279 20303
2024-05-30 8-K 8-K 5.02,7.01,9.01 0001193125-24-149802 001-40522 241000706 34 175250 1 1
2024-05-16 8-K 8-K 1.01,9.01 0001193125-24-140533 001-40522 24955534 34 657190 1 1
2024-05-16 424B5 424B5 0001193125-24-140518 333-266003 24955445 33 573187
2024-05-15 424B5 424B5 0001193125-24-139354 333-266003 24950253 33 573201
2024-05-13 SC 13D/A NEW ENTERPRISE ASSOCIATES 17, L.P. -- MONTE ROSA THERAPEUTICS 13D/A(#1) 0001072613-24-000471 005-92649 24941114 34 476792
2024-05-09 10-Q 10-Q 0000950170-24-056288 001-40522 24928624 34 6693730 1 1
2024-05-09 8-K 8-K 2.02,7.01,9.01 0000950170-24-056253 001-40522 24928502 34 36452109 1 1
2024-05-02 8-K 8-K 5.02,7.01,9.01 0000950170-24-052055 001-40522 24908039 34 208749 1 1
2024-05-01 144 xsl144X01/primary_doc.xml 0001974158-24-000034 001-40522 24903429 33 11336
2024-04-26 ARS ARS 0000950170-24-049093 001-40522 24883575 34 13892902
2024-04-26 DEFA14A DEFA14A 0000950170-24-049075 001-40522 24883476 34 3298610
2024-04-26 DEF 14A DEF 14A 0000950170-24-049065 001-40522 24883362 34 7941867
2024-04-10 144 xsl144X01/primary_doc.xml 0001974158-24-000022 001-40522 24836093 33 4396
2024-04-10 SC 13G/A glue13gamar24.txt 0000080255-24-000836 005-92649 34 7126
2024-03-14 S-8 S-8 0000950170-24-031455 333-277929 24750151 33 169502
2024-03-14 10-K 10-K 0000950170-24-031150 001-40522 24747948 34 24407553 1 1
2024-03-14 8-K 8-K 2.02,7.01 0000950170-24-031138 001-40522 24747899 34 31587485 1 1
2024-02-14 SC 13G SC 13G 0001104659-24-023735 005-92649 24638764 34 98737
2024-02-14 SC 13G/A AMENDMENT NO. 3 0000929638-24-000644 005-92649 24636508 34 150019
2024-02-14 SC 13G/A us61225m1027_021424.txt 0001086364-24-007037 005-92649 24634347 34 12545
2024-02-14 SC 13G/A glue13gadec23.txt 0000080255-24-000762 005-92649 34 7129
2024-02-14 SC 13G/A MONTE ROSA THERAPEUTICS, INC. 0000902664-24-001601 005-92649 24632983 34 59009
2024-02-09 SC 13G/A filing.txt 0000315066-24-001315 005-92649 24611866 34 8236
2024-01-08 8-K 8-K 7.01,9.01 0000950170-24-002696 001-40522 24518367 34 26731406 1 1
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000767 5593
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000768 6437
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000766 5714
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000764 6420
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000769 5607
2024-01-04 4 FORM 4 SUBMISSION 0001209191-24-000765 8073
2023-11-09 SC 13D/A SC 13D/A 0001193125-23-274637 005-92649 231393912 34 122198
2023-11-09 10-Q 10-Q 0000950170-23-061995 001-40522 231392236 34 8999706 1 1
2023-11-09 8-K 8-K 2.02,9.01 0000950170-23-061530 001-40522 231390059 34 513998 1 1
2023-10-26 8-K 8-K 1.01,8.01,9.01 0001193125-23-264162 001-40522 231350898 34 437017 1 1
2023-10-26 424B5 424B5 0001193125-23-264155 333-266003 231350851 33 486319
2023-10-17 8-K 8-K 1.01,7.01,8.01 0000950170-23-053653 001-40522 231328464 34 41943859 1 1
2023-08-18 3 FORM 3 SUBMISSION 0001209191-23-046513 12457
2023-08-15 144 xsl144X01/primary_doc.xml 0001963745-23-000051 001-40522 231175763 33 4398
2023-08-10 10-Q 10-Q 0000950170-23-040959 001-40522 231157182 34 8075642 1 1
2023-08-10 8-K 8-K 2.02,9.01 0000950170-23-040956 001-40522 231157174 34 554191 1 1
2023-07-26 4 FORM 4 SUBMISSION 0001209191-23-043408 5440
2023-07-26 3 FORM 3 SUBMISSION 0001209191-23-043404 7604
2023-07-26 8-K 8-K 5.02 0000950170-23-034560 001-40522 231110074 34 186859 1 1
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037376 5410
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037355 5477
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037354 5495
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037352 5551
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037350 5457
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037348 5502
2023-06-14 8-K 8-K 5.03,5.07,9.01 0000950170-23-027939 001-40522 231014097 34 293121 1 1
2023-05-11 10-Q 10-Q 0000950170-23-021201 001-40522 23910871 34 7142963 1 1
2023-05-11 8-K 8-K 2.02,9.01 0000950170-23-020846 001-40522 23908853 34 484771 1 1
2023-04-26 ARS ARS 0000950170-23-014798 001-40522 23849775 34 3205701
2023-04-26 DEFA14A DEFA14A 0000950170-23-014787 001-40522 23849720 34 3366088
2023-04-26 DEF 14A DEF 14A 0000950170-23-014779 001-40522 23849643 34 1574037
2023-04-12 PRE 14A PRE 14A 0000950170-23-012558 001-40522 23815757 34 1574200
2023-03-31 4 FORM 4 SUBMISSION 0001209191-23-021859 5421
2023-03-24 3 FORM 3 SUBMISSION 0001209191-23-021072 7486
2023-03-23 8-K 8-K 5.02 0000950170-23-009320 001-40522 23754475 34 185192 1 1
2023-03-16 S-8 S-8 0000950170-23-008471 333-270607 23738962 33 221692
2023-03-16 10-K 10-K 0000950170-23-008440 001-40522 23738744 34 21815553 1 1
2023-03-16 8-K 8-K 2.02,7.01,9.01 0000950170-23-008304 001-40522 23737149 34 28432502 1 1
2023-02-14 SC 13G/A sc13g.htm 0000929638-23-000565 005-92649 23627760 34 148199
2023-02-14 SC 13G/A glue13gadec22.txt 0000080255-23-002733 005-92649 34 6884
2023-02-14 SC 13G/A MONTE ROSA THERAPEUTICS, INC. 0000902664-23-001689 005-92649 23623545 34 60399
2023-02-09 SC 13G/A filing.txt 0000315066-23-001955 005-92649 23604823 34 8150
2023-02-03 SC 13G us61225m1027_020323.txt 0001306550-23-007642 005-92649 23586196 34 13279
2023-01-09 8-K 8-K 7.01,9.01 0000950170-23-000436 001-40522 23516585 34 19817703 1 1
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-000958 5505
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-000956 5489
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-000957 5485
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-000952 5491
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-000949 5592
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-000953 5487
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-000951 5471
2023-01-04 4 FORM 4 SUBMISSION 0001209191-23-000948 5485
2022-12-19 4 FORM 4 SUBMISSION 0001209191-22-061947 5704
2022-11-10 10-Q 10-Q 0000950170-22-024447 001-40522 221377093 34 8006055 1 1
2022-11-10 8-K 8-K 2.02,9.01 0000950170-22-024165 001-40522 221374966 34 487432 1 1
2022-11-01 4 FORM 4 SUBMISSION 0001209191-22-055037 5704
2022-10-24 8-K FORM 8-K 7.01,9.01 0001193125-22-267232 001-40522 221324943 34 9846885 1 1
2022-08-11 10-Q 10-Q 0000950170-22-016844 001-40522 221155616 34 7227175 1 1
2022-08-11 8-K 8-K 2.02,9.01 0000950170-22-016647 001-40522 221153714 34 2168574 1 1
2022-07-13 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-07-13 16:00:00 9999999995-22-002061 333-266003 221082144 33 1735
2022-07-11 CORRESP filename1.htm 0001193125-22-190944 5488
2022-07-08 UPLOAD filename1.pdf 0000000000-22-007225 40225
2022-07-01 S-3 S-3 0001193125-22-187284 333-266003 221062196 33 1399830
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037527 5375
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037432 5457
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037429 5513
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037427 5419
2022-06-16 4 FORM 4 SUBMISSION 0001209191-22-037421 5464
2022-06-15 8-K 8-K 5.07 0000950170-22-011697 001-40522 221018490 34 205554 1 1
2022-06-08 DEFA14A DEFA14A 0000950170-22-011328 001-40522 221003641 34 84809
2022-05-11 10-Q 10-Q 0000950170-22-009324 001-40522 22913792 34 6488708 1 1
2022-05-11 8-K 8-K 2.02,9.01 0000950170-22-009141 001-40522 22912096 34 2150090 1 1
2022-04-28 DEFA14A DEFA14A 0000950170-22-006556 001-40522 22867158 34 245881
2022-04-27 DEF 14A DEF 14A 0000950170-22-006371 001-40522 22859660 34 1209793
2022-03-29 S-8 S-8 0001193125-22-088225 333-263953 22781703 33 63955
2022-03-29 10-K 10-K 0000950170-22-004927 001-40522 22780942 34 14161669 1 1
2022-03-29 8-K 8-K 2.02,9.01 0000950170-22-004851 001-40522 22777381 34 405959 1 1
2022-03-02 4 FORM 4 SUBMISSION 0000899243-22-008711 5514
2022-03-02 4 FORM 4 SUBMISSION 0000899243-22-008707 5393
2022-03-02 4 FORM 4 SUBMISSION 0000899243-22-008706 5404
2022-03-02 4 FORM 4 SUBMISSION 0000899243-22-008705 5413
2022-03-02 4 FORM 4 SUBMISSION 0000899243-22-008698 5404
2022-03-02 4 FORM 4 SUBMISSION 0000899243-22-008694 5409
2022-03-02 3 FORM 3 SUBMISSION 0000899243-22-008691 10066
2022-03-02 4 FORM 4 SUBMISSION 0000899243-22-008681 5427
2022-03-02 4 FORM 4 SUBMISSION 0000899243-22-008673 5411
2022-02-14 SC 13G/A sc13g.htm 0000929638-22-000481 005-92649 22630212 34 153652
2022-02-11 SC 13G MONTE ROSA THERAPEUTICS, INC. 0000902664-22-001524 005-92649 22617351 34 64329
2022-02-10 SC 13G/A glue13gajan22.txt 0000080255-22-000973 005-92649 34 6856
2022-02-10 SC 13G glue13gdec21.txt 0000080255-22-000962 005-92649 34 6846
2022-02-09 SC 13G/A us61225m1027_020922.txt 0000834237-22-008617 005-92649 22608350 34 12282
2022-02-09 SC 13G/A filing.txt 0000315066-22-001069 005-92649 22604436 34 8424
2022-02-04 SC 13G us61225m1027_020422.txt 0000834237-22-007347 005-92649 22593607 34 13161
2022-01-10 8-K 8-K 7.01,9.01 0001193125-22-005070 001-40522 22519699 34 17202963 1 1
2021-12-15 8-K 8-K 1.01,2.03 0001193125-21-357931 001-40522 211494382 34 148294 1 1
2021-12-02 3 FORM 3 SUBMISSION 0000899243-21-046613 10178
2021-11-12 8-K 8-K 2.02,9.01 0001193125-21-326406 001-40522 211398584 34 240434 1 1
2021-11-10 10-Q 10-Q 0000950170-21-004138 001-40522 211397402 34 7107970 1 1
2021-08-12 10-Q 10-Q 0000950170-21-001372 001-40522 211167901 34 6456759 1 1
2021-08-12 8-K FORM 8-K 2.02,9.01 0000950123-21-010438 001-40522 211165601 34 239791 1 1
2021-08-10 SC 13G filing.txt 0000315066-21-001693 005-92649 211158816 34 8456
2021-07-12 SC 13D NEW ENTERPRISE ASSOCIATES 17, L.P. / MONTE ROSA THERAPEUTICS, INC. -- SCHEDULE 1 0001072613-21-000469 005-92649 211085496 34 530737
2021-07-08 SC 13D SC 13D 0001193125-21-210842 005-92649 211080516 34 168635
2021-07-08 SC 13G a20210539_sc13g.htm 0000929638-21-000881 005-92649 211080214 34 168006
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044051 17906
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044050 17948
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044048 17910
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044045 17818
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044044 17953
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044043 17923
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044042 17912
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044041 17916
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044040 17950
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044039 17902
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044037 17914
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044035 17816
2021-06-30 4 FORM 4 SUBMISSION 0001209191-21-044033 20641
2021-06-30 4 FORM 4 SUBMISSION 0000899243-21-026769 19439
2021-06-30 4 FORM 4 SUBMISSION 0000899243-21-026766 28143
2021-06-30 4 FORM 4 0001567619-21-012781 20497
2021-06-28 8-K 8-K 5.03,9.01 0001193125-21-202038 001-40522 211053711 34 149376
2021-06-25 4 FORM 4 SUBMISSION 0001209191-21-043356 5252
2021-06-25 4 FORM 4 SUBMISSION 0000899243-21-025983 8584
2021-06-25 4 FORM 4 SUBMISSION 0000899243-21-025982 5313
2021-06-25 4 FORM 4 SUBMISSION 0000899243-21-025981 5391
2021-06-25 4 FORM 4 SUBMISSION 0000899243-21-025977 8525
2021-06-25 4 FORM 4 SUBMISSION 0000899243-21-025980 8532
2021-06-25 4 FORM 4 SUBMISSION 0000899243-21-025976 8636
2021-06-25 4 FORM 4 SUBMISSION 0000899243-21-025984 8624
2021-06-25 4 FORM 4 SUBMISSION 0000899243-21-025979 5405
2021-06-25 4 FORM 4 SUBMISSION 0000899243-21-025978 14654
2021-06-25 4 FORM 4 SUBMISSION 0000899243-21-025975 5297
2021-06-25 S-8 S-8 0001193125-21-200331 333-257406 211047675 33 397169
2021-06-25 424B4 424B4 0001193125-21-199386 333-256773 211044636 33 9130325
2021-06-23 SEC STAFF LETTER filename1.pdf 9999999997-21-003614 271844
2021-06-23 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2021-06-23 16:00:00 9999999995-21-002471 333-256773 211040478 33 1735
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042883 7542
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042882 7584
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042880 7546
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042878 7454
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042876 7589
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042875 7559
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042874 7548
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042873 7552
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042871 7586
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042869 7538
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042868 7550
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042866 7452
2021-06-23 3 FORM 3 SUBMISSION 0001209191-21-042864 10729
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025636 7599
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025635 10070
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025631 10015
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025630 7687
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025624 14979
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025622 7605
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025615 10719
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025613 7662
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025606 10079
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025600 10923
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025593 8932
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025583 10115
2021-06-23 3 FORM 3 SUBMISSION 0000899243-21-025575 19024
2021-06-23 S-1MEF S-1MEF 0001193125-21-197580 333-257330 211040164 33 49740
2021-06-23 3 FORM 3 0001567619-21-012551 14790
2021-06-22 CERT 8ACERT_GLUE.pdf 0001354457-21-000689 001-40522 211034288 34 161419
2021-06-21 8-A12B 8-A12B 0001193125-21-195045 001-40522 211030550 34 14854
2021-06-21 CORRESP filename1.htm 0001193125-21-195023 11788
2021-06-21 CORRESP filename1.htm 0001193125-21-195011 10449
2021-06-21 CORRESP filename1.htm 0001193125-21-194066 22824
2021-06-21 S-1/A S-1/A 0001193125-21-194056 333-256773 211027188 33 10941648
2021-06-15 UPLOAD filename1.pdf 0000000000-21-007359 43227
2021-06-11 CORRESP filename1.htm 0001193125-21-188875 66430
2021-06-09 CORRESP filename1.htm 0001193125-21-186843 22915
2021-06-09 S-1/A S-1/A 0001193125-21-186830 333-256773 211005694 33 9207889
2021-06-07 UPLOAD filename1.pdf 0000000000-21-007037 46272
2021-06-04 S-1 S-1 0001193125-21-182268 333-256773 21995093 33 12630834
2021-05-25 SEC STAFF LETTER filename1.pdf 9999999997-21-003025 272646
2021-05-21 DRSLTR filename1.htm 0000950123-21-007251 48790
2021-05-21 DRS/A filename1.htm 0000950123-21-007249 377-04684 21949640 33 9173765

Latest XBRL company facts

One latest value per concept from companyfacts (277 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 85.45M 2026-10-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
dei EntityPublicFloat Entity Public Float USD 212.00M 2025-06-30 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap AccountsPayableAndOtherAccruedLiabilitiesCurrent Accounts Payable and Other Accrued Liabilities, Current USD 33.41M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 3.35M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 9.00M 2024-06-30 2024 Q2 10-Q 2024-08-08 0000950170-24-093296
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 1.94M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 33.41M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 33.69M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -6.19M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.06B 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 6.32M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AdministrativeFeesExpense Administrative Fees Expense USD 31.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 18.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AmortizationOfIntangibleAssets Amortization of Intangible Assets USD 2.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax USD -833,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap Assets Assets USD 697.73M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AssetsCurrent Assets, Current USD 640.07M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 589.43M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 9,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 2.37M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 534.91M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap AvailableForSaleDebtSecuritiesGrossUnrealizedLoss Debt Securities, Available-for-sale, Unrealized Loss USD 118,000 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-07 0000950170-25-104550
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 532.55M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 734,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 45.18M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 577.70M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 50.10M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -84.74M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 33.41M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 500.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 85.43M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 85.43M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap CommonStockValue Common Stock, Value, Issued USD 9,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -87.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 31.07M 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap CurrentFederalStateAndLocalTaxExpenseBenefit Current Federal, State and Local, Tax Expense (Benefit) USD -1.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD -865,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD -232,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-sale, Realized Gain (Loss) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DebtSecuritiesAvailableForSaleRealizedLoss Debt Securities, Available-for-sale, Realized Loss USD 2.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DebtSecuritiesAvailableForSaleUnrealizedGainLoss Debt Securities, Available-for-sale, Unrealized Gain (Loss) USD -1.08M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 514.40M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 9.78M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DeferredRevenue Deferred Revenue USD 102.26M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 21.10M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 83.41M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 9.78M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 52.87M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 13,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 10.04M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation USD 5.43M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 73.63M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs USD 0 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities Liability, Defined Benefit Pension Plan USD 0 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042344
us-gaap DefinedBenefitPensionPlanLiabilitiesNoncurrent Liability, Defined Benefit Pension Plan, Noncurrent USD 5.13M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DefinedBenefitPlanActualReturnOnPlanAssets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) USD 253,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanActuarialGainLoss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) USD 833,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanAdministrationExpenses Defined Benefit Plan, Plan Assets, Administration Expense USD 200,000 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-11 0000950170-23-021201
us-gaap DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate pure 0.014 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets pure 0.014 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase pure 0.013 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanBenefitObligation Defined Benefit Plan, Benefit Obligation USD 17.70M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanBenefitObligationBenefitsPaid Defined Benefit Plan, Benefit Obligation, Benefits Paid USD 343,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant USD 219,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanContributionsByEmployer Defined Benefit Plan, Plan Assets, Contributions by Employer USD 973,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years USD 7.42M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths Defined Benefit Plan, Expected Future Benefit Payment, Year One USD 1.17M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive Defined Benefit Plan, Expected Future Benefit Payment, Year Five USD 1.27M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour Defined Benefit Plan, Expected Future Benefit Payment, Year Four USD 1.25M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree Defined Benefit Plan, Expected Future Benefit Payment, Year Three USD 1.23M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo Defined Benefit Plan, Expected Future Benefit Payment, Year Two USD 1.20M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanFairValueOfPlanAssets Defined Benefit Plan, Plan Assets, Amount USD 12.44M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) USD 2.01M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanInterestCost Defined Benefit Plan, Interest Cost USD 9,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap DefinedBenefitPlanNetPeriodicBenefitCost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) USD 1.37M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanOtherChanges Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change USD -26,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DefinedBenefitPlanPlanAmendments Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanPlanAssetsBenefitsPaid Defined Benefit Plan, Plan Assets, Benefits Paid USD 343,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant Defined Benefit Plan, Plan Assets, Contributions by Plan Participant USD 219,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) USD 1.42M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedBenefitPlanServiceCost Defined Benefit Plan, Service Cost USD 1.23M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 1.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay pure 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match pure 0.04 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap Depreciation Depreciation USD 6.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DividendsPayableCurrentAndNoncurrent Dividends Payable USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap DividendsPreferredStockStock Dividends, Preferred Stock, Stock USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares 0.51 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-11 0000950170-22-009324
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0.028 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.007 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure -0.036 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042344
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure -0.056 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042344
us-gaap EffectiveIncomeTaxRateReconciliationGiltiAmount EffectiveIncomeTaxRateReconciliationGiltiAmount USD -70,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap EffectiveIncomeTaxRateReconciliationGiltiPercent EffectiveIncomeTaxRateReconciliationGiltiPercent pure 0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.003 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.139 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.005 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsOther Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent pure 0.002 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042344
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0.047 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 9.33M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 25.10M 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations USD -1.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap FinanceLeaseLiability Finance Lease, Liability USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap FinancialLiabilitiesFairValueDisclosure Financial Liabilities Fair Value Disclosure USD 19.68M 2020-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD 110,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 31.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap ImpairmentOfLongLivedAssetsToBeDisposedOf Impairment of Long-Lived Assets to be Disposed of USD 100,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -23.08M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -83.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD -16.65M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncomeLossFromContinuingOperationsPerBasicShare Income (Loss) from Continuing Operations, Per Basic Share USD/shares -0.84 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap IncomeLossFromContinuingOperationsPerDilutedShare Income (Loss) from Continuing Operations, Per Diluted Share USD/shares -0.84 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 5.18M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 976,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 4.61M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncomeTaxPaidStateAndLocalAfterRefundReceived IncomeTaxPaidStateAndLocalAfterRefundReceived USD 572,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 259,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -8.31M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 97,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 5.48M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncomeTaxReconciliationOtherReconcilingItems Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount USD 44,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -183,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD -1.85M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -519,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 0 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-07 0000950170-25-104550
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD 6.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -17.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -1.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD 6.00M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap IncreaseDecreaseInOtherReceivables Increase (Decrease) in Other Receivables USD 3.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 853,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap InterestExpenseOther Interest Expense, Other USD 140,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 17.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap LaborAndRelatedExpense Labor and Related Expense USD 13.49M 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-07 0001193125-26-210358
us-gaap LandSubjectToGroundLeases Land Subject to Ground Leases sqft 63,327 2021-12-14 2022 Q1 10-Q 2022-05-11 0000950170-22-009324
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 2.30M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap LeaseCost Lease, Cost USD 7.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap Liabilities Liabilities USD 201.52M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 697.73M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap LiabilitiesCurrent Liabilities, Current USD 62.05M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap MarketableSecurities Marketable Securities USD 532.55M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap MarketableSecuritiesGainLoss Marketable Securities, Gain (Loss) USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-09 0000950170-24-056288
us-gaap MarketableSecuritiesRealizedGainLoss Marketable Securities, Realized Gain (Loss) USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-09 0000950170-24-056288
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 332.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -294.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -122.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -84.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 17.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-06 0001193125-26-336711
us-gaap OperatingExpenses Operating Expenses USD 168.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -101.10M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap OperatingLeaseCost Operating Lease, Cost USD 4.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 7.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 7.40M 2022-01-01 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 4.19M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 32.08M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 23.34M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 81.00M 2021-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 8.35M 2021-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 7.30M 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 7.30M 2021-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 8.82M 2021-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 8.58M 2021-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 44.78M 2021-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 3.16M 2021-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.098 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 767,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent Other Comprehensive (Income) Loss, Defined Benefit Plan, before Tax, after Reclassification Adjustment, Attributable to Parent USD -1.59M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD 500,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax USD 756,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax USD -161,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap OtherGeneralAndAdministrativeExpense Other General and Administrative Expense USD 10.11M 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-07 0001193125-26-210358
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 1.65M 2025-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-268045
us-gaap OtherOwnershipInterestsOfferingCosts Other Ownership Interests, Offering Costs USD 1.00M 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap OtherReceivables Other Receivables USD 4.61M 2026-03-31 2026 Q1 10-Q 2026-05-07 0001193125-26-210358
us-gaap OtherReceivablesNetCurrent Other Receivables, Net, Current USD 7.62M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap OtherResearchAndDevelopmentExpense Other Research and Development Expense USD 35.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap PaymentOfFinancingAndStockIssuanceCosts Payment of Financing and Stock Issuance Costs USD 357,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap PaymentsForRent Payments for Rent USD 95 2021-12-14 2022 Q1 10-Q 2022-05-11 0000950170-22-009324
us-gaap PaymentsForRepurchaseOfInitialPublicOffering Payments for Repurchase of Initial Public Offering USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap PaymentsForTenantImprovements Payments for Tenant Improvements USD 13.00M 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-268045
us-gaap PaymentsOfDividends Payments of Dividends USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 290,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 499.78M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 8.15M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent Liability, Defined Benefit Plan USD 5.26M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap PensionExpense Pension Cost (Reversal of Cost) USD 1.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2023-12-31 2023 FY 10-K 2024-03-14 0000950170-24-031150
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2023-12-31 2023 FY 10-K 2024-03-14 0000950170-24-031150
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 4.71M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 0 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-268045
us-gaap ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan USD 527,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042344
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity USD 345.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042344
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042344
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 7.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ProfessionalAndContractServicesExpense Professional and Contract Services Expense USD 6.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -84.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 62.33M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 28.63M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 137.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap RestrictedCash Restricted Cash USD 4.92M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents USD 326.10M 2025-03-31 2025 Q1 10-Q 2025-05-08 0000950170-25-066372
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 0 2023-12-31 2023 FY 10-K 2024-03-14 0000950170-24-031150
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 4.92M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -562.05M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap RevenueFromContractWithCustomerIncludingAssessedTax Revenue from Contract with Customer, Including Assessed Tax USD 67.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 18.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value USD 1.50M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.841 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.044 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 45.91M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 9.78M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 8.12 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 1.62M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-10 0000950170-21-004138
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 127,377 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 2.94M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 5.16 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 62.72M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 15.87M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 9.22 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 62.72M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price USD/shares 9.22 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 82.19M 2021-09-30 2021 Q3 10-Q 2021-11-10 0000950170-21-004138
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 5.57M 2021-09-30 2021 Q3 10-Q 2021-11-10 0000950170-21-004138
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 7.58 2021-09-30 2021 Q3 10-Q 2021-11-10 0000950170-21-004138
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 15.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value USD/shares 1.13 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 7.62 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 9.71 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 15.73 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap SharesIssuedPricePerShare Shares Issued, Price Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042344
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 496.21M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Stock Issued During Period, Shares, Conversion of Convertible Securities shares 31.07M 2021-06-01 2021-06-30 2022 Q1 10-Q 2022-05-11 0000950170-22-009324
us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Stock Issued During Period, Shares, Employee Stock Purchase Plans shares 46,960 2026-04-01 2026-06-30 2026 Q2 10-Q 2026-08-06 0001193125-26-336711
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 13.00M 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-07 0001193125-26-210358
us-gaap StockIssuedDuringPeriodSharesOther Stock Issued During Period, Shares, Other shares 0 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-20 0000950170-25-042344
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 1.01M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 231.17M 2021-04-01 2021-06-30 2021 Q2 10-Q 2021-08-12 0000950170-21-001372
us-gaap StockIssuedDuringPeriodValueConversionOfUnits Stock Issued During Period, Value, Conversion of Units USD 231.17M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008440
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 611,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap StockIssuedDuringPeriodValueIssuedForServices Stock Issued During Period, Value, Issued for Services USD 87,000 2024-01-01 2024-03-31 2025 Q1 10-Q 2025-05-08 0000950170-25-066372
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 323.81M 2026-01-01 2026-03-31 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 568,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 325.88M 2022-03-31 2022 Q1 10-Q 2022-05-11 0000950170-22-009324
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 0 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 0 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap TemporaryEquityValueExcludingAdditionalPaidInCapital Temporary Equity, Par Value USD 0 2021-12-31 2021 FY 10-K 2022-03-29 0000950170-22-004927
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 1.50M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-109360
us-gaap VariableLeaseCost Variable Lease, Cost USD 2.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 101.06M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 46.60M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-11 0000950170-22-009324
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 101.06M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448568

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →